Abstract
PURA-related neurodevelopmental disorders (PURA-NDDs) include 5q31.3 microdeletion syndrome and PURA syndrome. PURA has been proposed as a candidate gene responsible for 5q31.3 microdeletion syndrome. Phenotype comparisons between patients with PURA mutations and 5q31.3 microdeletions encompassing more than PURA gene are lacking. A total of 25 previously undescribed Mainland China patients were evaluated. Clinical data were obtained from medical record review and standardized medical history questionnaire. Clinical profile and genetic spectrum of the patients with PURA syndrome and genotype–phenotype correlations between PURA mutations group and 5q31.3 microdeletions group were analyzed. Our identified seventeen de nove PURA variants were novel, and two recurrent frameshift variants, c.697_699del (p.F233del) and c.159dup (p.L54Afs*147) were detected in the four independent pedigrees. One patient with 5q31.3 microdeletion further supported the shortest overlapping region only contains PURA and IGIP gene. Developmental delay/intellectual disability, neonatal hypotonia, neonatal feeding difficulties, hypersomnolence and dysmorphic features were prominent clinical features in PURA syndrome. There was no significant difference between two groups in incidence of neonatal problems, developmental delay and common medical comorbidities. We observed a higher frequency of abnormal brain MRI and specific facial dysmorphism in 5q31.3 microdeletion group. This is the first work describing a largest cohort of Mainland China patients broaden the clinical and molecular spectrum of PURA-NDDs. Our findings not only demonstrated that PURA haploinsufficiency was a major contributor to the important phenotypes of 5q31.3 microdeletion, but also implied that additional genes still played a role in the 5q31.3 microdeletion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.




Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).
References
Reijnders MRF, Leventer RJ, Lee BH, Baralle D, Selber P, Paciorkowski AR, et al. PURA-Related Neurodevelopmental Disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle Copyright © 1993-2022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.
Shimojima K, Isidor B, Le Caignec C, Kondo A, Sakata S, Ohno K, et al. A new microdeletion syndrome of 5q31.3 characterized by severe developmental delays, distinctive facial features, and delayed myelination. Am J Med Genet Part A. 2011;155a:732–6.
Hosoki K, Ohta T, Natsume J, Imai S, Okumura A, Matsui T, et al. Clinical phenotype and candidate genes for the 5q31.3 microdeletion syndrome. Am J Med Genet Part A. 2012;158a:1891–6.
Brown N, Burgess T, Forbes R, McGillivray G, Kornberg A, Mandelstam S, et al. 5q31.3 Microdeletion syndrome: clinical and molecular characterization of two further cases. Am J Med Genet Part A. 2013;161a:2604–8.
Bonaglia MC, Zanotta N, Giorda R, D’Angelo G, Zucca C. Long-term follow-up of a patient with 5q31.3 microdeletion syndrome and the smallest de novo 5q31.2q31.3 deletion involving PURA. Mol Cytogenet. 2015;8:89.
Choi SA, Lee HS, Park TJ, Park S, Ko YJ, Kim SY, et al. Expanding the clinical phenotype and genetic spectrum of PURA-related neurodevelopmental disorders. Brain Dev. 2021;43:912–8.
Khalili K, Del Valle L, Muralidharan V, Gault WJ, Darbinian N, Otte J, et al. Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol Cell Biol. 2003;23:6857–75.
Hokkanen S, Feldmann HM, Ding H, Jung CK, Bojarski L, Renner-Müller I, et al. Lack of Pur-alpha alters postnatal brain development and causes megalencephaly. Hum Mol Genet. 2012;21:473–84.
Kuo CJ, Lee KH, Huang CC, Wang IF, Hsieh CC, Lin HC, et al. Purα regulates the induction of Znf179 transcription during neuronal differentiation. Biochem Biophys Res Commun. 2020;533:1477–83.
Lalani SR, Zhang J, Schaaf CP, Brown CW, Magoulas P, Tsai AC, et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome. Am J Hum Genet. 2014;95:579–83.
Hunt D, Leventer RJ, Simons C, Taft R, Swoboda KJ, Gawne-Cain M, et al. Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability. J Med Genet. 2014;51:806–13.
Reijnders MRF, Janowski R, Alvi M, Self JE, van Essen TJ, Vreeburg M, et al. PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature. J Med Genet. 2018;55:104–13.
Shimojima K, Okamoto N, Ohmura K, Nagase H, Yamamoto T. Infantile spasms related to a 5q31.2-q31.3 microdeletion including PURA. Hum Genome Var. 2018;5:18007.
Tanaka AJ, Bai R, Cho MT, Anyane-Yeboa K, Ahimaz P, Wilson AL, et al. De novo mutations in PURA are associated with hypotonia and developmental delay. Cold Spring Harb Mol case Stud. 2015;1:a000356.
Okamoto N, Nakao H, Niihori T, Aoki Y. Patient with a novel purine-rich element binding protein A mutation. Congenit Anom. 2017;57:201–4.
Rezkalla J, Von Wald T, Hansen KA. Premature Thelarche and the PURA Syndrome. Obstet Gynecol. 2017;129:1037–9.
Lee BH, Reijnders MRF, Abubakare O, Tuttle E, Lape B, Minks KQ, et al. Expanding the neurodevelopmental phenotype of PURA syndrome. Am J Med Genet Part A. 2018;176:56–67.
Liu Y, Liu R, Xu T, Zhou YX, Zhang SC. Neonatal PURA syndrome: a case report and literature review. Transl Pediatr. 2021;10:194–203.
Johannesen KM, Gardella E, Gjerulfsen CE, Bayat A, Rouhl RPW, Reijnders M, et al. PURA-related developmental and epileptic encephalopathy: phenotypic and genotypic spectrum. Neurol Genet. 2021;7:e613.
Lin SJ, Lin YF, Tsai CH, Huang CH, Ho F, Tsai SF, et al. Complex movement disorders in a boy with PURA syndrome. Mov Disord Clin Pract. 2021;8:1137–9.
Spangenberg L, Guecaimburú R, Tapié A, Vivas S, Rodríguez S, Graña M, et al. Novel frameshift mutation in PURA gene causes severe encephalopathy of unclear cause. Mol Genet Genom Med. 2021;9:e1622.
Kwong AK, Tsang MH, Fung JL, Mak CC, Chan KL, Rodenburg RJT, et al. Exome sequencing in paediatric patients with movement disorders. Orphanet J Rare Dis. 2021;16:32.
Mroczek M, Zafeiriou D, Gurgel-Gianetti J, Vilela Morais de Azevedo B, Roos A, Bartels E, et al. Three individuals with PURA syndrome in a Cohort of patients with neuromuscular disease. Neuropediatrics. 2021;52:390–3.
Cinquina V, Ciaccio C, Venturini M, Masson R, Ritelli M, Colombi M. Expanding the PURA syndrome phenotype: A child with the recurrent PURA p.(Phe233del) pathogenic variant showing similarities with cutis laxa. Mol Genet Genom Med. 2021;9:e1562.
Boczek NJ, Macke EL, Kemppainen J, Klee EW, Renaud DL, Gavrilova RH. Expansion of PURA-related phenotypes and discovery of a novel PURA variant: a case report. Child Neurol Open. 2020;7:2329048x20955003.
Rodríguez-García ME, Cotrina-Vinagre FJ, Arranz-Canales E, Aragón AM, Hernández-Sánchez L, Rodríguez-Fornés F, et al. A novel de novo mutation in the PURA gene associated with a new clinical finding: large brainstem. J Genet. 2020;99:7.
Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22:245–57.
Weber J, Bao H, Hartlmüller C, Wang Z, Windhager A, Janowski R, et al. Structural basis of nucleic-acid recognition and double-strand unwinding by the essential neuronal protein Pur-alpha. eLife. 2016;5:e11297.
Aumiller V, Graebsch A, Kremmer E, Niessing D, Förstemann K. Drosophila Pur-α binds to trinucleotide-repeat containing cellular RNAs and translocates to the early oocyte. RNA Biol. 2012;9:633–43.
Graebsch A, Roche S, Niessing D. X-ray structure of Pur-alpha reveals a Whirly-like fold and an unusual nucleic-acid binding surface. Proc Natl Acad Sci USA. 2009;106:18521–6.
Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14–30.
Acknowledgements
We would like to acknowledge the affected patients and their families for the participation in the study. We also acknowledged Yue Tao for structural protein model.
Funding
This work was supported by the National Key R&D Program of China (No. 2019YFC1005100, to YGY); the National Natural Science Foundation of China (No. 82101950, to NX); Shanghai Municipal Commission of Health and Family Planning (No. 20204Y0453, to NX); the National Natural Science Foundation of China (No.81873671 and No. 82070914, to YGY); the Shanghai Science and Technology Commission (No. 19140904500, to YGY); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20191908, to YGY).
Author information
Authors and Affiliations
Contributions
KS, YY and NX: conception and design of the study; WD and NX: drafting the paper or figures; YS: review and editing the paper; BX and WD: evaluation of the pictures of individuals for the morphological analysis; YF, YG, LW and YZ: acquisition and analysis of data. BX, WQ and XG: providing partial clinical data. All authors read and approved the final paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The study was conducted with the approval of Ethics Committee of Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University (XHEC-D-2022-064).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dai, W., Sun, Y., Fan, Y. et al. A 25 Mainland Chinese cohort of patients with PURA-related neurodevelopmental disorders: clinical delineation and genotype–phenotype correlations. Eur J Hum Genet 31, 112–121 (2023). https://doi.org/10.1038/s41431-022-01217-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41431-022-01217-4
This article is cited by
-
New year, new genes
European Journal of Human Genetics (2023)